Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AEO, a patented molecule, is MetVital's lead clinical development drug candidate and has been approved for commercial Phase 2 testing of Glioblastoma multiforme, a malicious type of brain cancer, and the seizures caused by the cancer.
Lead Product(s): Enol-oxaloacetate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: National Institute of Neurological Disorders
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 24, 2020
Details:
U.S. Food and Drug Administration (FDA) has notified MetVital that its lead drug candidate, "Anhydrous Enol-Oxaloacetate" (AEO) received Fast Track Designation for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM).
Lead Product(s): Enol-oxaloacetate,Temozolomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020